Tang Capital Management’s Beam Therapeutics BEAM Stock Holding History

Tang Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-255,000	Closed	-$6.19M	–	92
2025 Q3	$6.19M	Buy	255,000 +50,000	+24%	+$995K	0.24%	87
2025 Q2	$3.49M	Buy	205,000 +155,000	+310%	+$2.7M	0.18%	102
2025 Q1	$977K	Hold	50,000	–	–	0.05%	156
2024 Q4	$1.24M	Sell	50,000 -120,000	-71%	-$3.06M	0.08%	125
2024 Q3	$4.17M	Sell	170,000 -100,000	-37%	-$2.58M	0.3%	81
2024 Q2	$6.33M	Buy	+270,000	New	+$6.63M	0.64%	49
2024 Q1	–	Sell	-350,000	Closed	-$9.53M	–	105
2023 Q4	$9.53M	Buy	+350,000	New	+$8.69M	0.88%	31
2023 Q1	–	Sell	-95,000	Closed	-$3.72M	–	108
2022 Q4	$3.72M	Buy	95,000 +45,000	+90%	+$2.02M	0.54%	44
2022 Q3	$2.38M	Buy	+50,000	New	+$2.85M	0.29%	68

Other funds holding BEAM

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Tang Capital Management's BEAM Position: Q4 2025 in Review

Tang Capital Management sold out of Beam Therapeutics (BEAM) in Q4 2025, closing a stake of 255,000 shares — an estimated $6.19M sold.

Tang Capital Management first reported a position in BEAM in Q3 2022 and held it in 9 quarters. The position peaked at $9.53M in Q4 2023. 246 funds tracked by Wall St. Rank hold BEAM as of Q4 2025.

Tang Capital Management reported no remaining Beam Therapeutics position as of Q4 2025 after selling out during the quarter.
Tang Capital Management sold 255,000 Beam Therapeutics shares in Q4 2025, an estimated $6.19M.
Tang Capital Management first reported a position in Beam Therapeutics in Q3 2022 and held it in 9 quarters.
Tang Capital Management's Beam Therapeutics position peaked at $9.53M in Q4 2023.
246 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2025.

Based on Tang Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.